S
Saby George
Researcher at Roswell Park Cancer Institute
Publications - 167
Citations - 14398
Saby George is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 31, co-authored 138 publications receiving 10182 citations. Previous affiliations of Saby George include Memorial Sloan Kettering Cancer Center & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma
Madelon Q. Wentink,Henk M.W. Verheul,Sumanta K. Pal,Saby George,Johannes Voortman,Pongwut Danchaivijitr,Remi Adelaiye,Diane Poslinski,Adrienne Groman,Alan D. Hutson,Roberto Pili +10 more
TL;DR: The increased anti‐factor Xa levels during combination treatment suggest that sunitinib might increase the anticoagulation activity of dalteparin, and the positive safety profile warrants prospective evaluation of the clinical benefit of this combination strategy in patients with ccRCC.
Journal ArticleDOI
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.
Jean-Francois Martini,Elizabeth R. Plimack,Toni K. Choueiri,David F. McDermott,Igor Puzanov,Igor Puzanov,Mayer Fishman,Daniel C. Cho,Ulka N. Vaishampayan,Bradley Rosbrook,Kathrine C. Fernandez,Jamal Tarazi,Saby George,Michael B. Atkins +13 more
TL;DR: With combined axitinib/pembrolizumab treatment in patients with aRCC, mostly immune-related biomarkers are associated with better treatment outcomes.
Journal ArticleDOI
Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma
Saby George,Robert Dreicer,J. Au,Tong Shen,Brian I. Rini,Susan Roman,Matthew M. Cooney,Tarek Mekhail,Paul Elson,Guillaume M. Wientjes,Ram Ganapathi,Ronald M. Bukowski +11 more
TL;DR: Suramin levels expected to reverse fibroblast growth factor-induced resistance can be achieved with the dosing regimen used in this study, and the combination does not have clinical activity in patients with metastatic RCC.
Journal ArticleDOI
Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214
Viktor Grünwald,Toni K. Choueiri,Brian I. Rini,Thomas Powles,Saby George,M.-O. Grimm,M.B. McHenry,Matthew Maurer,Robert J. Motzer,Hans J. Hammers,Nizar M. Tannir,Laurence Albiges +11 more
Journal ArticleDOI
Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).
Michael B. Atkins,Elizabeth R. Plimack,Igor Puzanov,Mayer Fishman,David F. McDermott,Daniel C. Cho,Ulka N. Vaishampayan,Saby George,Thomas Olencki,Jamal Tarazi,Brad Rosbrook,Kathrine C. Fernandez,Mariajose Lechuga,Toni K. Choueiri +13 more
TL;DR: This data indicates that pre-existing studies combining programmed death-1 checkpoint inhibitors with tyrosine kinase inhibitors of the vascular endothelial growth factor pathway have been characterIZed as positive for PD-1 checkpoints and VEGF checkpoint blockade is likely to be beneficial.